Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Read More…
Industry, Sector and Symbol
Industry N/A
Sub-IndustryPharmaceuticals
SectorN/A
WebN/A
PhoneN/A
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees92,400
Next Earnings Date5/5/2020 (Estimated)
OptionableOptionable
Pfizer (NYSE:PFE) Frequently Asked Questions
What is Pfizer's stock symbol?
Pfizer trades on the New York Stock Exchange (NYSE) under the ticker symbol "PFE."
How often does Pfizer pay dividends? What is the dividend yield for Pfizer?
Pfizer announced a quarterly dividend on Monday, December 16th. Investors of record on Friday, January 31st will be given a dividend of $0.38 per share on Friday, March 6th. This represents a $1.52 annualized dividend and a yield of 4.16%. The ex-dividend date is Thursday, January 30th. This is an increase from Pfizer's previous quarterly dividend of $0.36. View Pfizer's Dividend History.
How will Pfizer's stock buyback program work?
Pfizer announced that its Board of Directors has initiated a share buyback plan on Friday, December 14th 2018, which allows the company to repurchase $10,000,000,000.00 in shares, according to EventVestor. This repurchase authorization allows the company to reacquire up to 3.8% of its shares through open market purchases. Shares repurchase plans are usually an indication that the company's board of directors believes its shares are undervalued.
How were Pfizer's earnings last quarter?
Pfizer Inc. (NYSE:PFE) announced its quarterly earnings data on Tuesday, January, 28th. The biopharmaceutical company reported $0.55 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.57 by $0.02. The biopharmaceutical company earned $12.69 billion during the quarter, compared to analysts' expectations of $12.73 billion. Pfizer's revenue was down 9.2% compared to the same quarter last year. During the same period last year, the business earned $0.64 earnings per share. View Pfizer's Earnings History.
When is Pfizer's next earnings date?
What guidance has Pfizer issued on next quarter's earnings?
Pfizer updated its FY20 earnings guidance on Tuesday, January, 28th. The company provided EPS guidance of $2.82-$2.92 for the period, compared to the Thomson Reuters consensus estimate of $2.72. The company issued revenue guidance of $48.5-$50.5 billion, compared to the consensus revenue estimate of $47.44 billion.
What price target have analysts set for PFE?
12 analysts have issued 12-month price objectives for Pfizer's stock. Their forecasts range from $36.00 to $53.00. On average, they anticipate Pfizer's stock price to reach $42.03 in the next twelve months. This suggests a possible upside of 15.1% from the stock's current price. View Analyst Price Targets for Pfizer.
What is the consensus analysts' recommendation for Pfizer?
12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pfizer in the last year. There are currently 8 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Pfizer.
What are Wall Street analysts saying about Pfizer stock?
Here are some recent quotes from research analysts about Pfizer stock:
- 1. According to Zacks Investment Research, "The Consumer Healthcare joint venture with Glaxo, the Array acquisition and the pending merger of Upjohn unit with Mylan, if successful, will make Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines. The smaller Pfizer should see better revenue growth as the Lyrica LOE cliff will go away. Pfizer expects continued strong growth of key brands like Ibrance and Eliquis and biosimilars to drive sales in the second half. Pfizer is also strengthening its pipeline and hopes to launch new innovative medicines in the next five years, which can drive long-term growth. However, currency headwinds, weak sales in the sterile injectables portfolio, pricing pressure and some recent negative product developments for Prevnar and Xeljanz, are top-line headwinds. Shares have underperformed the industry this year so far. " (10/1/2019)
- 2. Cantor Fitzgerald analysts commented, "We reiterate our OW rating and think respectable earnings growth, driven by Innovative Medicines, pipeline advancements, and return of capital to PFE’s shareholders — above the industry average — are all underappreciated. Therefore, we believe multiple expansion and upward earnings revisions should drive PFE shares higher. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $53." (2/19/2019)
Has Pfizer been receiving favorable news coverage?
Media headlines about PFE stock have trended neutral this week, InfoTrie Sentiment reports. InfoTrie identifies negative and positive news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Pfizer earned a media sentiment score of 0.2 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for Pfizer.
Who are some of Pfizer's key competitors?
Some companies that are related to Pfizer include AbbVie (ABBV), The Medicines (MDCO), Assembly Biosciences (ASMB), Ampio Pharmaceuticals (AMPE), Melinta Therapeutics (MLNT), Acura Pharmaceuticals (ACUR), Akorn (AKRX), Allergan (AGN), BioDelivery Sciences International (BDSI), Bristol-Myers Squibb (BMY), Corcept Therapeutics (CORT), Cumberland Pharmaceuticals (CPIX), Eli Lilly And Co (LLY), Endo International (ENDP) and Horizon Therapeutics (HZNP).
What other stocks do shareholders of Pfizer own?
Who are Pfizer's key executives?
Pfizer's management team includes the folowing people:
- Mr. Ian C. Read, Exec. Chairman (Age 65)
- Mr. Albert Bourla D.V.M., DVM, Ph.D., CEO & Director (Age 57)
- Mr. Frank A. D'Amelio, CFO & EVP of Global Supply & Bus. Operations (Age 61)
- Dr. Mikael Dolsten, Chief Scientific Officer & Pres of Worldwide Research, Devel. and Medical (Age 60)
- Mr. John D. Young, Group Pres & Chief Bus. Officer (Age 54)
Who are Pfizer's major shareholders?
Pfizer's stock is owned by a number of of institutional and retail investors. Top institutional investors include State Street Corp (5.27%), Bank of New York Mellon Corp (1.08%), Massachusetts Financial Services Co. MA (0.94%), Charles Schwab Investment Management Inc. (0.72%), LSV Asset Management (0.54%) and Franklin Resources Inc. (0.52%). Company insiders that own Pfizer stock include Alexander R Mackenzie, Charles H Hill, Dawn Rogers, Douglas M Lankler, Frank A Damelio, Ian C Read, Kirsten Lund-Jurgensen, Laurie J Olson, Loretta V Cangialosi, Mikael Dolsten, Pfizer Inc, Rady A Johnson, Sally Susman, Scott Gottlieb and W Don Cornwell. View Institutional Ownership Trends for Pfizer.
Which major investors are selling Pfizer stock?
PFE stock was sold by a variety of institutional investors in the last quarter, including Massachusetts Financial Services Co. MA, PGGM Investments, California Public Employees Retirement System, LSV Asset Management, CI Investments Inc., PNC Financial Services Group Inc., KBC Group NV and State of Tennessee Treasury Department. Company insiders that have sold Pfizer company stock in the last year include Alexander R Mackenzie, Dawn Rogers, Frank A Damelio, Mikael Dolsten and Rady A Johnson. View Insider Buying and Selling for Pfizer.
Which major investors are buying Pfizer stock?
PFE stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Marshall Wace North America L.P., Sanders Capital LLC, Bank of New York Mellon Corp, FIL Ltd, Sound Shore Management Inc. CT, Marshall Wace LLP and Stifel Financial Corp. Company insiders that have bought Pfizer stock in the last two years include Pfizer Inc and Scott Gottlieb. View Insider Buying and Selling for Pfizer.
How do I buy shares of Pfizer?
Shares of PFE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Pfizer's stock price today?
One share of PFE stock can currently be purchased for approximately $36.51.
MarketBeat Community Rating for Pfizer (NYSE PFE)
MarketBeat's community ratings are surveys of what our community members think about Pfizer and other stocks. Vote "Outperform" if you believe PFE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PFE will underperform the S&P 500 over the long term. You may vote once every thirty days.
